Sanofi has announced plans to invest more than EUR 600 million ($705 million) to build a new manufacturing vaccine facility in Toronto to increase supply of its influenza vaccines for Canada, the US, and Europe.

The new facility will provide additional antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine. Fluzone High-Dose Quadrivalent influenza vaccine is currently manufactured exclusively by Sanofi Pasteur, Sanofi’s vaccines global business unit, at the company’s Swiftwater, Pennsylvania site. Sanofi Pasteur has been investing in expanding manufacturing capabilities for influenza vaccines. Two new additional facilities in Swiftwater, Pennsylvania and Val-de-Reuil, France will start to operate in the coming years (as reported on March 31, 2021).

Sanofi expects this new facility to be operational in 2026, following design, construction, testing and qualification of the facility and equipment.

In 2018, Sanofi invested EUR 335 million ($394 million) at the Toronto site for bulk vaccine manufacturing, which at the time, was its largest investment globally. The manufacturing facility will produce seven antigens: five-component-pertussis plus diphtheria and tetanus. License approval for the US and Canada is expected in 2024 for the five-component-pertussis and in 2025 for diphtheria and tetanus.

Source: Sanofi